Modal Day Analysis of Self Monitoring Blood Glucose Versus Continuous Glucose Monitoring
Type 2 Diabetes

About this trial
This is an interventional treatment trial for Type 2 Diabetes focused on measuring Type 2 Diabetes, A1c, Continuous Glucose Monitoring, Blood Glucose
Eligibility Criteria
Inclusion Criteria:
- Male or female subjects ≥18 and ≤75 years of age
- Clinical diagnosis of diabetes
- Diabetes duration ≥ 1 year
- HbA1c ≥7.2%
- Diabetes can be treated with any therapy including medical nutrition therapy alone and any pharmaceutical therapy
Exclusion Criteria:
- Taken prednisone or cortisone medications in the previous 30 days
- Currently pregnant or planning pregnancy during the study period
- Presence of any severe medical or psychological condition or chronic conditions/infections that in the opinion of the Investigator would compromise the subject's safety or successful participation in the study
- Unable to follow the study protocol
- Unable to speak, read and write in English
Sites / Locations
- International Diabetes Center
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
SMBG Only
SMBG and CGM
You will measure your blood glucose 4 times daily by finger sticks using a blood glucose meter and you will also wear a CGM device. The CGM measurements will be blinded (neither you nor the study doctor will be able to see the CGM measurements until your final study visit). Only your SMBG measurements will be considered to help manage your diabetes. Your medications will be changed or adjusted based on your HbA1c and/or glucose readings with a goal to achieve an HbA1c level of less than 7%.
You will measure your blood glucose 4 times daily by finger sticks using a blood glucose meter and you will also wear a CGM device. The CGM measurements will be downloaded at each study visit and will be considered along with your SMBG measurements to help manage your diabetes. Your medications will be changed or adjusted based on your HbA1c and/or glucose readings with a goal to achieve an HbA1c level of 7%.